Efficacy and Safety of Combination Antifungals as Empirical, Preemptive, and Targeted Therapies for Invasive Fungal Infections in Intensive-Care Units

References

• Lilienfeld-Toal MV, Wagener J, Einsele H, et al. Invasive fungal infection. Dtsch Arztebl Int. 2019;116(16):271–278. doi:10.3238/arztebl.2019.0271
   Web of Science ®Google Scholar
• Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence. 2014;5(1):161–169. doi:10.4161/viru.26187
   PubMed Web of Science ®Google Scholar
• Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med Wkly. 2016;146. doi:10.4414/smw.2016.14281
   Web of Science ®Google Scholar
• Ibrahim-Granet OG, Rekiki A, Savers A, et al. New insights into the pathogenesis of invasive pulmonary aspergillosis: real time imaging of hypoxia and inflammation. Mycoses. 2013;56:145–146. doi:10.1111/j.1439-0507.2012.02224.x
   Web of Science ®Google Scholar
• Cortes LJ, Russi NJ. Equinocandinas. Rev Chilena Infectol. 2011;28(6):529–536. Spanish.
   Web of Science ®Google Scholar
• Hargrove TY, Wawrzak Z, Lamb DC, et al. Structure-functional characterization of cytochrome P450 sterol 14alpha-demethylase (CYP51B) from aspergillus fumigatus and molecular basis for the development of antifungal drugs. J Biol Chem. 2015;290(39):23916–23934. doi:10.1074/jbc.M115.677310
   PubMed Web of Science ®Google Scholar
• Fukasawa M. リソーマルアムホテリシンB. Nihon Ishinkin Gakkai Zasshi. 2005;46(4):229–231. Japanese. doi:10.3314/jjmm.46.229
   Google Scholar
• Perea S, Gonzalez G, Fothergill AW, et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of aspergillus spp. Antimicrob Agents Chemother. 2002;46(9):3039–3041. doi:10.1128/aac.46.9.3039-3041.2002
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002;46(8):2564–2568. doi:10.1128/AAC.46.8.2564-2568.2002
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89. doi:10.7326/M13-2508
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46(1):245–247. doi:10.1128/AAC.46.1.245-247.2002
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, et al. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother. 2005;49(12):4867–4875. doi:10.1128/AAC.49.12.4867-4875.2005
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107(12):2888–2897. doi:10.1002/cncr.22348
   PubMed Web of Science ®Google Scholar
• Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740–2746. doi:10.1002/cncr.23109
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. doi:10.1093/cid/civ933
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Muilwijk EW, Schouten JA, Van Leeuwen HJ, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother. 2014;69(12):3294–3299. doi:10.1093/jac/dku313
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–1151. doi:10.1016/S0140-6736(03)14472-8
   PubMed Web of Science ®Google Scholar
• De Pascale G, Tumbarello M. Fungal infections in the ICU: advances in treatment and diagnosis. Curr Opin Crit Care. 2015;21(5):421–429. doi:10.1097/MCC.0000000000000230
   PubMed Web of Science ®Google Scholar
• Martin-Pena A, Aguilar-Guisado M, Espigado I, et al. Antifungal combination therapy for invasive aspergillosis. Clin Infect Dis. 2014;59(10):1437–1445. doi:10.1093/cid/ciu581
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563–1571. doi:10.1086/423381
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–571. doi:10.1086/324620
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383–1396. doi:10.1086/516353
   PubMed Web of Science ®Google Scholar
• Lee DG, Lee HJ, Yan JL, et al. Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis. Mycoses. 2019;62(10):969–978. doi:10.1111/myc.12972
   Web of Science ®Google Scholar
• Qiu KY, Liao XY, Fang JP, et al. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders. Transpl Infect Dis. 2019;21(3):e13066. doi:10.1111/tid.13066
   Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–299. doi:10.1002/cncr.11479
   PubMed Web of Science ®Google Scholar
• Haidar G, Singh N. How we approach combination antifungal therapy for invasive aspergillosis and mucormycosis in transplant recipients. Transplantation. 2018;102(11):1815–1823. doi:10.1097/TP.0000000000002353
   Web of Science ®Google Scholar
• Mihu CN, Kassis C, Ramos ER, et al. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer. 2010;116(22):5290–5296. doi:10.1002/cncr.25312
   Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821. doi:10.1086/588660
   PubMed Web of Science ®Google Scholar
• Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother. 2011;66(Suppl 1):i25–35. doi:10.1093/jac/dkq439
   Web of Science ®Google Scholar
• Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–1785. doi:10.1093/jac/dkw045
   PubMed Web of Science ®Google Scholar
• Sideri G, Falagas ME, Grigoriou M, et al. Liposomal amphotericin B in critically ill paediatric patients. J Clin Pharm Ther. 2012;37(3):291–295. doi:10.1111/j.1365-2710.2011.01288.x
   Web of Science ®Google Scholar
• Silva S, Negri M, Henriques M, et al. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288–305. doi:10.1111/j.1574-6976.2011.00278.x
   PubMed Web of Science ®Google Scholar
• Garbati MA, Alasmari FA, Al-Tannir MA, et al. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. Int J Infect Dis. 2012;16(2):e76–81. doi:10.1016/j.ijid.2011.10.004
   Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Shoham S, Vazquez J, et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58(9):1219–1226. doi:10.1093/cid/ciu074
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37. doi:10.1111/1469-0691.12039
   PubMed Web of Science ®Google Scholar
• Cui N, Wang H, Qiu H, et al. Impact of initial empirical antifungal agents on the outcome of critically ill patients with invasive candidiasis: analysis of the China-SCAN study. Int J Antimicrob Agents. 2017;50(1):74–80. doi:10.1016/j.ijantimicag.2017.02.019
   Web of Science ®Google Scholar
• Leon-Gil C, Ubeda-Iglesias A, Loza-Vazquez A, et al. Efficacy and safety of caspofungin in critically ill patients. ProCAS study. Rev Esp Quimioter. 2012;25(4):274–282.
   PubMed Web of Science ®Google Scholar
• Dupont H, Mahjoub Y, Chouaki T, et al. Antifungal prevention of systemic candidiasis in immunocompetent ICU adults: systematic review and meta-analysis of clinical trials. Crit Care Med. 2017;45(11):1937–1945. doi:10.1097/CCM.0000000000002698
   Web of Science ®Google Scholar
• Raad II, Zakhem AE, Helou GE, et al. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45(3):283–288. doi:10.1016/j.ijantimicag.2014.08.012
   PubMed Web of Science ®Google Scholar
• Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2014;28:80–94. doi:10.1016/j.ijid.2014.07.007
   PubMed Web of Science ®Google Scholar
• Thomas A, Korb V, Guillemain R, et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm Ther. 2010;35(1):49–53. doi:10.1111/j.1365-2710.2009.01061.x
   Web of Science ®Google Scholar
• O’Shaughnessy EM, Meletiadis J, Stergiopoulou T, et al. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006;58(6):1168–1176. doi:10.1093/jac/dkl392
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97(4):1025–1032. doi:10.1002/cncr.11115
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797–802. doi:10.1086/423380
   PubMed Web of Science ®Google Scholar